THE CORRELATION BETWEEN FRAMINGHAM RISK SCORE AND THE CLINICAL AND BIOCHEMICAL PARAMETERS THAT MEASURE FUNCTIONAL DISABILITY AND DISEASE ACTIVITY IN IRAQI PATIENTS WITH RHEUMATOID ARTHRITIS
Objective: Rheumatoid arthritis (RA) patients have increased morbidity and mortality from premature cardiovascular (CV) disease (CVD). Framingham risk score (FRS) is a simplified coronary prediction tool developed to enable clinicians to assess the risk of a cardiovascular event and to identify candidate patients for risk factors modifications worldwide. The predictive ability of the FRS varies between populations, ethnic groups, and socio-economic status. The aim of this study is to find if there is any correlation between the Framingham risk score and the inflammatory and biochemical parameters used to measure disease activity and functional ability in Iraqi patients with active RA.
Methods: A cross-sectional study was conducted in the rheumatology outpatient unit of Baghdad Teaching Hospital, from September 2012 to April 2013. A total of 140 patients (40 males and 100 females) with active RA were involved in this study. Disease activity was measured by disease activity score of 28 joints (DAS28) and the simplified disease activity index (SDAI); whereas functional status of the patients were measured using The patient reported outcomes measurement information System (PROMIS HAQ) score. The FRS was calculated using a computerized formula from the web. Then the correlation between FRS with clinical parameters (DAS28, SDAI and PROMIS HAQ), plus the biochemical parameter (hsCRP, TNF and ESR) was determined.
Result: There was a significant positive correlation between FRS and both of (DAS28 and SDAI). Additionally FRS was significantly correlated with each of (TNF, ESR and hsCRP).
Conclusion: We found a significant correlation between FRS and the two most important methods used to measure disease activity (DAS28 and SDAI) but to obtain more significant result with other clinical parameter, long-term prospective studies with a larger sample size are needed.
2. Sattar N, McCarey DW, Capell H, McInnes IB. Explaining how "high-grade" systemic inflammation accelerates vascular risk in rheumatoid arthritis. Circulation 2003;108:2957â€“63.
3. Konstantinos T, Petros P, Antonios K, et al. Myocardial ischemia without obstructive coronary artery disease in rheumatoid arthritis: hypothesis-generating insights from a cross-sectional study. Oxford JMR 2013;52(1):76-80.
4. Gabriel SE. Heart disease and rheumatoid arthritis: understanding the risks. Ann RD 2010;69(1):61â€“4.
5. Blaha MJ, De Filippis AP, Rivera J. Associations between C-reactive protein, coronary artery calcium, and cardiovascular events: implications for the JUPITER population from MESA, a population-based cohort study. Lancet 2011;20:378:684.
6. Conroy R, Pyorala K, Fitzgerald A, et al. Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart 2003;24:987â€“1003.
7. Dâ€™Agostino R, Vasan R, Pencina M, et al. General cardiovascular risk profile for use in primary care: the Framingham Heart Study. Circulation 2008;117:743â€“53.
8. Liew SM, Doust J, Glasziou P. Cardiovascular risk scores do not account for the effect of treatment: a review. Heart 2011;97:689â€“97.
9. Brindle P, Beswick A, Fahey T, Ebrahim S. Accuracy and impact of risk assessment in the primary prevention of cardiovascular disease: a systematic review. Heart 2006;92:1752â€“9.
10. Prevoo ML, vanâ€™t Hof MA, Kuper HH, et al. Modified disease activity scores that include twenty-eight-joint counts (Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis). Arthritis Rheum 1995;38:44-8.
11. Smolen JS, Breedveld FC, Schiff MH, et al. A simplified disease activity index for rheumatoid arthritis for use in clinical practice. Rheumatology 2003;42:244-57.
12. National Committee for Clinical Laboratory Standards (NCCLS). Reference and Selected Procedure for the Erythrocyte Sedimentation Rate (ESR) Test; Approved Standard-Fourth Edition. NCCLS document H2-A4, Wayne, PA, USA 2000.
13. Mitra B, Panja M. High sensitive C-reactive protein: a novel biochemical markers and its role in coronary artery disease. JAI 2005;53:25-32.
14. So T, Lee SW, Croft M. Tumor necrosis factor/ tumor necrosis receptor family members that positively regulate immunity. IJ Hematol 2006;83(1):1-11.
15. Cecilia PC, Annette O, Ingrid A, et al. Utility of the Framingham risk score to predict the presence of coronary atherosclerosis in patients with rheumatoid arthritis. Arthritis Res Therapy 2006;8:186-92.
16. 16-Meiattini F, Prencipe L, Bardelli F, et al. The 4-hydroxybenzoate/4-aminophenazone chromogenic system used in the enzymic determination of serum cholesterol. Clin Chem 1978;24(12):2161-5.
17. Maria FL, Pamela S, Shelton E, John AC. Cholesterol determination in high density lipoproteins separated by three different methods. Clin Chem 1977;23(5):882-4.
18. 18-Aletaha D, Smolen J. The Simplified Disease Activity Index (SDAI) and the Clinical Disease Activity Index (CDAI): a review of their usefulness and validity in rheumatoid arthritis. Clin ER 2005;23(5 Suppl 39):S100-8.
19. 19-Cella D, Yount S, Rothrock N, et al. The patient reported outcomes measurement information system (PROMIS): progress of an NIH roadmap cooperative group during its first two years. Medical Care 2007;45:S3-S11.
20. Naranjo A, Sokka T, Descalzo MA, et al. Cardiovascular disease in patients with rheumatoid arthritis: results from the QUEST-RA study. Arthritis RT 2008;10:30.
21. 21-Mustafa GÙ€LER, Saadet YAZGAN UMUT, Teoman AYDIN, et al. The correlation between cardiovascular risk and functional disability and disease activity in patients with rheumatoid arthritis. Turk JMS 2013;43:919-27.
22. Ford ES, Giles WH. Serum C-reactive protein and fibrinogen concentrations and self-reported angina pectoris and myocardial infarction: findings from National Health and Nutrition Examination Survey III. JCE 2000;53:95â€“102.
23. Albert MA, Glynn RJ, Ridker PM. Plasma concentration of C-reactive protein and the calculated framingham coronary heart disease risk score. Circulation 2003;108:161â€“5.
24. Alissa EM, Bahjri SM, Al-Ama N, et al. High cardiovascular risk in young Saudi males: cardiovascular risk factors, diet and inflammatory markers. Clin CA 2006;365:288â€“96.
25. Cheongmin Sohn, Juyong Kim, Wookyung Bae. The framingham risk score, diet, and inflammatory markers in Korean men with metabolic syndrome. Nutr RP 2012;6:246-53.
26. Rho YH, Chung CP, Oeser A, Solus J, et al. Inflammatory mediators and premature coronary atherosclerosis in rheumatoid arthritis. Arthritis Rheum 2009;61:1580â€“5.
27. Van Leuven SI, Franssen R, Kastelein JJ, Levi M, et al. Systemic inflammation as a risk factor for atherothrombosis. Rheumatology (Oxford) 2008;47:3â€“7.
28. Sattar N, McInnes IB. Vascular comorbidity in rheumatoid arthritis: potential mechanisms and solutions. Curr OR 2005;17:286â€“92.
29. Naz SM, Farragher TM, Bunn DK, et al. The influence of age at symptom onset and length of follow-up on mortality in patients with recent-onset inflammatory Polyarthritis. Arthritis Rheum 2008;58:985â€“9.
30. Cynthia S. Crowson, MS, Eric L. Matteson, et al. Usefulness of risk scores to estimate the risk of cardiovascular disease in patients with rheumatoid arthritis. Am JC 2012;110(3):420â€“4.